Performance in Delivering Clinical Research Q3 2014-15
Time to Target (Commercial Contracts)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Trial Status	Target met	Comments
10/H0606/69	RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics - Protocol No. NN25310	6	Closed - Follow Up Complete	No	Four participants recruited from six, viewed as successful by the sponsor becaure this study has proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this site was probably over ambitious.
10/H0604/94	RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics. Protocol No. NN25307	6	Closed - Follow Up Complete	No	This study has proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this stie was probably over ambitious.
11/SC/0383	Evaluation of the effects of agomelatine (25mg and 50mg) and escitalopram 20mg during 8 weeks on emotional blunting, emotional processing and motivation in healthy male and female volunteers.	64	Closed - Follow Up Complete	Yes	
12/SC/0213	Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of LuAA21004 on cognition and BOLD fMRI signals in subjects remitted from depression and controls	32	Closed - Follow Up Complete	No	30 participants were recruited. The study team were unable to recruit the final 2 controls and another UK site (Manchester) agreed to do this. The study recruited the target in the UK. 30 participants of 32 recruited equals 94%
12/SC/0544	A randomised, double-blind, placebo-controlled, dose-ranging, parallel-group, phase 2 study of the safety and efficacy of ABT-126 in the treatment of cognitive deficits in schizophrenia (CDS) in nonsmokers	3	Closed - Follow Up Complete	No	Recruited 2 out of 3 patients. The study has proven difficult to recruit to across all UK sites due to strict inclusion criteria.
12/NE/0410	A randomised, placebo-controlled, parallel-group, double-blind, efficacy and safety trial of MK-8931 in subjects with mild to moderate Azheimer's disease	8	Open	N/A	
12/EM/0391	A randomised, double blind, placebo controlled, phase 3 study to evaluate the efficacy and safety of once a day, TAK375 (Ramelteon) tablet for sub-lingual administration (TAK375SL tablet) 0.1mg and 0.4mg as an adjunctive therapy in the treatment of acute depressive episodes associated with Bipolar 1 disorder in adult subjects	5	Withdrawn	No	Sponsor closed the study early following interim analysis and recommendation from the DMC that the pre-determined efficacy criteria for study termination had been met.
13/SC/0386	Long term safety and efficacy of ABT-126 in subjects with schizophrenia: a double-blind extension study for subjects completing study M10-855	2	Closed - Follow Up Complete	No	Of the 2 participants who were eligible to proceed to the extension study; only one continued as the second participant withdrew consent to enter the extension study.
13/NW/0727	A randomised, double-blind, placebo-controlled, single-dose, study of the effects of SEP 363856 and Amisulpride on bold-FMRI signal in healthy male and female volunteers with high or low schizotype characteristics	54	Open	N/A	
13/LO/1758	A phase III. randomised, placebo controlled, parallel group, double blind clinical trial to study the efficacy and safety of MK8931 (SCH 900931) in subjects with amnestic mild cognitive impairment due to Alzheimer's Disease (Prodromal AD)	6	Open	N/A	